Latest Breaking News On - Oligonucleotide discovery - Page 2 : comparemela.com

Silence Therapeutics (NASDAQ:SLN) Earns Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $42.00 price target on the stock. A number of other analysts have also commented on SLN. BMO Capital Markets initiated coverage on Silence Therapeutics […]

Janus henderson groupVivo capitalParkman healthcare partnersMorgan stanleySg americas securitiesChardan capitalSilence therapeuticsFree reportGet free reportHealthcare partnersOligonucleotide discoverySilence therapeutics daily

Silence Therapeutics : Condensed consolidated income statement (unaudited) - Form 6-K

Condensed consolidated income statement Three months ended .

United kingdomUnited statesHong kongCity ofNew jerseyInternational financial reporting standardsEuropean unionInternational accounting standardFrazier life sciencesUk parliamentRedmile groupResearch collaborationJournal of the american medical associationPublic company accounting oversight boardInternational accounting standards boardAlnylam pharmaceuticals inc

Vivo Capital LLC Invests $8 86 Million in Silence Therapeutics plc (NASDAQ:SLN)

Vivo Capital LLC Invests $8 86 Million in Silence Therapeutics plc (NASDAQ:SLN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Morgan stanleySecurities exchange commissionSg americas securitiesVivo capitalSilence therapeuticsFree reportGet free reportOligonucleotide discoverySilence therapeutics daily

Morgan Stanley Reiterates Overweight Rating for Silence Therapeutics (NASDAQ:SLN)

Morgan Stanley Reiterates Overweight Rating for Silence Therapeutics (NASDAQ:SLN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Parkman healthcare partnersVivo capitalMorgan stanleySg americas securitiesSilence therapeuticsFree reportTherapeutics trading downGet free reportHealthcare partnersOligonucleotide discoverySilence therapeutics daily

Silence Therapeutics (LON:SLN) Stock Price Crosses Below 200 Day Moving Average of $535 00

Silence Therapeutics plc (LON:SLN – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 535 ($6.66) and traded as low as GBX 512 ($6.37). Silence Therapeutics shares last traded at GBX 535 ($6.66), with a volume of 913,528 shares trading hands. […]

Silence therapeuticsGet free reportOligonucleotide discoverySilence therapeutics dailyLon sln